The Week in Deregulation: November 20, 2026
The week's regulatory moves ranked, who won and lost, the idea scorecard after Friday's selloff, and every dated catalyst through January 19.
Seven days, seven stories, and a stock market that decided to end the week by falling 3.5 percent on Friday. The S&P 500 SPDR closed at $690.87, down 3.49 percent on the day, which is the backdrop for everything below.1 When the tape is red, deregulation stories tend to get ignored. That is usually the better time to read them.
Here is my ranked look back at the week in deregulation, who won, who lost, and how the six stock ideas from this week's articles are holding up. The scorecard is marked plainly: it is not investment advice and it is not a track record. It is me keeping score in public, entry price logged at publication against the November 20 close.
1. The HIPAA Privacy Rule Rewrite
The week's biggest move by page count and by reach. HHS published a 121-page final rule on November 19 that cuts the deadline for answering a patient's request for their own records from 30 days to 15, makes portal and app access free, and deletes the clipboard acknowledgment form along with six years of documentation requirements.2 The sleeper provision is a new permission to share health data with social services agencies and community organizations for care coordination, the plumbing of value-based care. HHS claims roughly $4 billion in savings against $1 billion in costs over five years. Winners: patients, managed care. Losers: small providers who eat the compliance bill. My take is here.
2. The FCC Erased Environmental Review for Most New Cell Sites
The FCC's NEPA modernization takes effect December 17, and it removes most wireless deployments that do not require Antenna Structure Registration from federal environmental review entirely.3 The agency's own analysts put the scale at 13,262 macro sites a year leaving review. Winners: carriers and tower owners. Losers: the environmental review industry and the litigation bar. The FCC's own welfare estimate, $169.5 million, is two orders of magnitude smaller than the industry numbers it cites, which is exactly the kind of honesty I like in a rulemaking. Full piece here.
3. The FCC Killed the 39 Percent Cap on TV Station Owners
The national multiple ownership rule that capped TV station groups at 39 percent of US households is repealed, effective January 11, 2027, replaced by case-by-case review (Free Markets Report, Nov. 15, 2026, citing 91 FR 72799). This is the one outright consolidation permission slip of the week. Winners: station groups with single-digit earnings multiples and acquisition appetite. Losers: anyone hoping broadcast stays fragmented. Sinclair, the idea from that piece, is the test case. Here.
4. The SEC Put Executive Pay Disclosure on a Diet
SEC Release 33-11455 cuts Item 402 executive compensation disclosure, and a companion filer-status proposal would exempt roughly 81 percent of public companies from being an accelerated filer, by the SEC's own estimate (Free Markets Report, Nov. 17, 2026, citing SEC Release 33-11455). Winners: small public companies that pay compliance teams by the hour. Losers: lawyers who bill them. The idea was the Russell 2000 ETF, on the theory that fixed-cost relief matters most to the smallest balance sheets. Here.
5. CMS Proposed Killing the $173 Million Training Rule
CMS proposed repealing the hospital emergency-readiness and training mandates that cost the industry about $173 million a year and consume 3.26 million staff hours (Free Markets Report, Nov. 16, 2026, citing 91 FR 72634). It is a proposal, not a final rule, so it ranks below the finished items. Winners if finalized: hospital operators, who get back labor hours at the worst possible staffing moment. Losers: none that I can find, which is rare in rulemaking. Here.
6. The FDA Wants to Cut a $636,732 Toll on Cancer Tests
The FDA proposed moving certain cancer-drug immunohistochemistry tests from class III premarket approval, a $636,732 fee with a 180-day review goal, to class II clearance at $28,653 and 90 days (Free Markets Report, Nov. 14, 2026, citing 91 FR 72825). Comments run to January 11, 2027. Winners: diagnostics makers and the labs that run these tests. Losers: incumbents whose moat was the toll itself, though Agilent, the incumbent I picked, helped write the request. Here.
7. The Index Concentration Argument
The Wednesday piece was not a rulemaking. It argued that seven stocks now make up roughly a third of the S&P 500, that a passive index buyer is making a concentrated tech bet whether they intend to or not, and that the deregulation trade is the other bet, with a different set of drivers than AI capex (Free Markets Report, Nov. 18, 2026). On a week when the index fell hard, the concentration question stops being academic. It carried no single-stock idea, so it sits at the bottom of this list by format, not by merit.
The Idea Scorecard
Entry prices were logged at publication, intraday on each article's day. Current prices are the November 20 close. Percentages are computed from those two numbers. This is not advice, and it is not a track record. It is a scorekeeping exercise, and I keep score on every idea.
| Ticker | Date | Entry | Nov 20 close | Change | Thesis status |
|---|---|---|---|---|---|
| AMT | Nov 19 | $181.29 | $184.25 | +1.6% | Only green idea of the week; Dec 17 effective date ahead |
| ELV | Nov 20 | $401.53 | $394.48 | -1.8% | One-day mark on a red tape day; thesis unchanged |
| A | Nov 14 | $173.96 | $170.38 | -2.1% | Comments to Jan 11; stock drifted with the market |
| IWM | Nov 17 | $269.35 | $257.04 | -4.6% | Small caps fell harder; disclosure thesis is a years story |
| SBGI | Nov 15 | $15.14 | $14.29 | -5.6% | Consolidation needs the Jan 11 effective date to matter |
| HCA | Nov 16 | $509.78 | $475.57 | -6.7% | Worst of the week, but up 3.3 percent Friday |
All quotes are from Perplexity Finance, November 20, 2026 close.4, 5, 6, 7, 8, 9 One honest note: five of six ideas are down since entry, and the S&P 500 fell 3.49 percent on Friday alone. A week is noise. I publish the scorecard anyway because the only scorecard worth anything is the one that shows the bad weeks too.

Who Won The Week
If you score the week by agency, HHS takes it. The HIPAA rule is the largest single document of the seven, it is final rather than proposed, and it carries the administration's own arithmetic showing savings ahead of costs in every year. The FCC takes second place with two finished rules, the environmental review rollback and the ownership cap repeal, plus a live comment file on robocall revocation. The FDA and CMS both filed proposals, which count as half-credit until the comment windows close in January. The SEC moved on disclosure, the smallest dollar story of the week but the one with the widest reach, because executive pay tables appear in every public company's proxy.
What I find notable is the pattern across all seven: not one of these rules abolished a regulator or fired a bureau. Each one cut a specific, countable cost, a fee, a form, a review requirement, a deadline, and left the underlying statute untouched. That is what deregulation looks like when it is done by people who expect to be audited. The savings are modest individually, roughly $31.5 million a year for the cell-site rule, $173 million for the hospital training rule, but they compound, and the direction of travel is now a year old and consistent.
What To Watch Next Week
Wednesday, November 25 is the busiest deregulation day on the calendar. The FCC's TCPA consent-revocation final rule takes effect that day, and comments are due the same day on the follow-up proposal to cut the ten-business-day window for honoring revocation requests.10, 11 Markets are closed Thursday for Thanksgiving. Then the calendar empties until December 3, when reply comments close on the FCC's historic-preservation question, the companion to the cell-site review rollback. December 17 brings the NEPA effective date. In January, the FCC ownership cap repeal and the FDA cancer-test comment deadline land on the same day, January 11, followed by the HIPAA effective date on January 19 (FMR catalyst calendar).

That is the week. Seven stories, six ideas, one falling market, and a calendar that gets loud again on Wednesday. If someone forwarded you this, you can join free at freemarketsreport.com and get the daily version.
Know someone who should be reading this?
One deregulation story and one stock idea, every day, free. Send it to someone who thinks markets work better than mandates.
The Free Markets Report is provided by Lead-Lag Publishing, LLC. All opinions and views mentioned in this report constitute our judgments as of the date of writing and are subject to change at any time. Information within this material is not intended to be used as a primary basis for investment decisions and should also not be construed as advice meeting the particular investment needs of any individual investor. Trading signals produced by the Free Markets Report are independent of other services provided by Lead-Lag Publishing, LLC or its affiliates, and positioning of accounts under their management may differ. Please remember that investing involves risk, including loss of principal, and past performance may not be indicative of future results. Lead-Lag Publishing, LLC, its members, officers, directors and employees expressly disclaim all liability in respect to actions taken based on any or all of the information on this writing. Nothing in this report shall be construed as an offer to provide investment advice or services. Nothing in this report shall be construed to be an offer to provide investment advisory services. Nothing in this report shall be construed as an offer or solicitation to buy or sell any security. The Free Markets Report is for informational purposes only and does not constitute a complete description of our investment services or performance. THE INFORMATION IN THIS REPORT HAS BEEN PREPARED WITHOUT REGARD TO THE INDIVIDUAL CIRCUMSTANCES OF INDIVIDUALS WHO MIGHT RECEIVE IT. THE INVESTMENTS DISCUSSED MAY NOT BE SUITABLE FOR ALL INVESTORS. INVESTORS MUST MAKE THEIR OWN INVESTMENT DECISIONS BASED ON THEIR OWN PARTICULAR FINANCIAL SITUATIONS AND OBJECTIVES. This report is not an offer to provide investment advice or services. Nothing in this report shall be construed as an offer to provide investment advice or services. Nothing in this report shall be construed to be an offer to provide investment advisory services in any jurisdiction in which Lead-Lag Publishing, LLC is not authorized to provide such services. All investments involve risk, including the risk of loss of principal. No representation is being made that any security, account, or strategy is or is likely to achieve results similar to those shown. Investing in securities involves risks, and there is always the potential of losing money when you invest in securities. Before investing, consider your investment objectives, and Lead-Lag Publishing, LLC's charges and expenses. This report is not a prospectus and does not contain all of the information necessary to fully evaluate any security or strategy discussed, including, but not limited to, the risk of adverse effects of related market developments. You should not rely solely on the information contained in this report, and should seek advice based on your situation from a licensed investment professional. Carefully consider the investment objectives, risks, charges, and expenses of any investment product before investing. This report may not be copied or distributed without the express written consent of Lead-Lag Publishing, LLC. Any decisions made based on any or all of the information in this writing are the sole responsibility of the user, and the user should exercise caution and take appropriate advice before acting.
Sources
- Perplexity Finance, SPY quote, Nov. 20, 2026 (perplexity.ai)
- Federal Register, 91 FR 74848, Nov. 19, 2026 (federalregister.gov)
- Federal Register, 91 FR 74041, Nov. 17, 2026 (federalregister.gov)
- AMT (perplexity.ai)
- ELV (perplexity.ai)
- A (perplexity.ai)
- IWM (perplexity.ai)
- SBGI (perplexity.ai)
- HCA (perplexity.ai)
- Federal Register, 91 FR 67214 (federalregister.gov)
- 91 FR 67239 (federalregister.gov)